Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Monday, February 4th.
Several other equities analysts also recently commented on SGMO. JPMorgan Chase & Co. downgraded shares of Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $35.00 to $11.00 in a research note on Wednesday, November 14th. BidaskClub downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. Guggenheim started coverage on shares of Sangamo Therapeutics in a research note on Tuesday, October 9th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Monday, November 19th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Sangamo Therapeutics currently has a consensus rating of “Hold” and an average price target of $16.60.
Shares of SGMO opened at $10.05 on Monday. The stock has a market capitalization of $901.48 million, a PE ratio of -14.36 and a beta of 2.84. Sangamo Therapeutics has a fifty-two week low of $6.26 and a fifty-two week high of $26.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.32 and a current ratio of 6.32.
In other news, VP Edward R. Conner sold 5,000 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $12.33, for a total value of $61,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 20,000 shares of company stock valued at $231,500 in the last three months. Company insiders own 1.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Sangamo Therapeutics by 29.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 1,552 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Sangamo Therapeutics during the 4th quarter worth approximately $102,000. Merriman Wealth Management LLC bought a new position in Sangamo Therapeutics during the 4th quarter worth approximately $119,000. Virtu Financial LLC bought a new position in Sangamo Therapeutics during the 4th quarter worth approximately $129,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Sangamo Therapeutics by 49.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,964 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 4,599 shares during the last quarter. Institutional investors and hedge funds own 62.46% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.